BioScrip Inc (BIOS) Receives $3.83 Consensus PT from Brokerages

BioScrip Inc (NASDAQ:BIOS) has been assigned an average rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $3.83.

BIOS has been the topic of several research reports. ValuEngine upgraded BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. BidaskClub upgraded BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price objective on BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th.

BioScrip (BIOS) traded up $0.06 on Friday, reaching $2.99. The company’s stock had a trading volume of 298,841 shares, compared to its average volume of 928,725. The stock has a market cap of $381.27, a P/E ratio of -4.82 and a beta of 0.19. BioScrip has a one year low of $1.35 and a one year high of $3.39. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN boosted its position in BioScrip by 1.0% during the 2nd quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after acquiring an additional 1,100 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in BioScrip by 0.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after acquiring an additional 2,622 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in BioScrip by 9.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock valued at $271,000 after acquiring an additional 8,914 shares in the last quarter. Voya Investment Management LLC boosted its position in BioScrip by 41.4% during the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after acquiring an additional 14,867 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in BioScrip by 10.2% during the 2nd quarter. Teachers Advisors LLC now owns 219,040 shares of the company’s stock valued at $595,000 after acquiring an additional 20,290 shares in the last quarter. 85.51% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “BioScrip Inc (BIOS) Receives $3.83 Consensus PT from Brokerages” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/22/bioscrip-inc-bios-receives-3-83-consensus-pt-from-brokerages.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply